Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Final results of BRIGHT AML 1003

Michael Heuser • 12 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Cytarabine Glasdegib
BRIGHT AML 1003

Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, discusses final 4-year overall survival results of BRIGHT AML 1003 (NCT01546038), a study investigating survival benefit of glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Michael Heuser

BAY1436032: IDH1 inhibition in IDH1-mutated AML
3:01
BAY1436032: IDH1 inhibition in IDH1-mutated AML
Michael Heuser • 2 Jun 2020
Is MRD monitoring prior to allograft standard in AML?
3:13
Is MRD monitoring prior to allograft standard in AML?
Michael Heuser • 25 Oct 2019
AML: mutant IDH1 inhibitor HMS-101
2:51
AML: mutant IDH1 inhibitor HMS-101
Michael Heuser • 25 Oct 2019
The clinical application of MRD testing in AML
1:30
The clinical application of MRD testing in AML
Michael Heuser • 1 Jun 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals